All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Nonstructural protein 3 (NS3), also known as p-70, is a viral nonstructural protein that is 70 kDa cleavage product of the hepatitis C virus polyprotein. It acts as a serine protease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-C176Z | Human anti-NS3 (CINGVCWTV) T cell receptor, pCDTCR1 | HCV | Human | CINGVCWTV | HLA-A2 | Lentiviral | ||
TCR-C177Z | Human anti-NS3 T cell receptor (AV38s2/BV11s1), pCDTCR1 | HCV | AV38s2/BV11s1 | Human | KLVALGINAV | HLA-A*0201 | Lentiviral | |
TCR-C178Z | Murinized anti-NS3 T cell receptor, pCDTCR1 | HCV | Murinized | aa 1406-1415 | HLA-A2 | Lentiviral | ||
TCR-C179Z | Human anti-NS3 T cell receptor (Leucine zipper TCR), pCDTCR1 | HCV | Human | aa 1406-1415 | HLA-A2 | Lentiviral | ||
TCR-C180Z | Mouse anti-NS3 T cell receptor (F8), pCDTCR1 | HCV | F8 | Mouse | CINGVCWTV | HLA-A2 | Lentiviral | |
TCR-C181Z | Mouse anti-NS3 T cell receptor (H4), pCDTCR1 | HCV | H4 | Mouse | CINGVCWTV | HLA-A2 | Lentiviral | |
TCR-C182Z | Human anti-NS3 T cell receptor (JK4), pCDTCR1 | DENV-4 | JK4 | Human | VIGLYGNGV | HLA-DR15 | Lentiviral | |
TCR-C183Z | Human anti-NS3 T cell receptor (JK43), pCDTCR1 | DENV-4 | JK43 | Human | VIGLYGNGV | HLA-DR15 | Lentiviral | |
TCR-L271 | Human anti-NS3 T cell receptor, pCDTCR1 | HCV | Human | aa 1406-1415 | HLA-A2 | Lentiviral | ||
TCR-L351 | Human anti-NS3 T cell receptor (I8H4), pCDTCR1 | HCV | I8H4 | Human | aa 1073-1081 | HLA-A2 | Lentiviral | |
TCR-L352 | Human anti-NS3 T cell receptor (I8A4), pCDTCR1 | HCV | I8A4 | Human | aa 1073-1081 | HLA-A2 | Lentiviral | |
TCR-L353 | Human anti-NS3 T cell receptor (I4G7), pCDTCR1 | HCV | I4G7 | Human | aa 1073-1081 | HLA-A2 | Lentiviral | |
TCR-L354 | Human anti-NS3 T cell receptor (I2B11), pCDTCR1 | HCV | I2B11 | Human | aa 1073-1081 | HLA-A2 | Lentiviral | |
TCR-L355 | Human anti-NS3 T cell receptor (I4E9), pCDTCR1 | HCV | I4E9 | Human | aa 1073-1081 | HLA-A2 | Lentiviral | |
TCR-L356 | Human anti-NS3 T cell receptor (I6B3), pCDTCR1 | HCV | I6B3 | Human | aa 1073-1081 | HLA-A2 | Lentiviral | |
TCR-L357 | Human anti-NS3 T cell receptor (I7B7), pCDTCR1 | HCV | I7B7 | Human | aa 1073-1081 | HLA-A2 | Lentiviral | |
TCR-L358 | Human anti-NS3 T cell receptor (I4F9), pCDTCR1 | HCV | I4F9 | Human | aa 1073-1081 | HLA-A2 | Lentiviral | |
TCR-YC0749 | Human anti-NS3 T cell receptor (D13), pCDTCR1 | DENV2 | D13 | Human | GTSGSPIVDR | HLA-A*11:01 | Lentiviral vector | |
TCR-YC0750 | Human anti-NS3 T cell receptor (D30), pCDTCR1 | DENV2 | D30 | Human | GTSGSPIVDR | HLA-A*11:01 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION